Vera Therapeutics (NASDAQ:VERA) Shares Up 6.2% – Here’s Why

Vera Therapeutics, Inc. (NASDAQ:VERA) was up 6.2% during trading on Monday . The company traded as high as $34.18 and last traded at $34.2870. Approximately 290,245 shares changed hands during mid-day trading, a decline of 80% from the average session volume of 1,461,276 shares. The stock had previously closed at $32.28.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on VERA shares. Needham & Company LLC set a $125.00 price objective on shares of Vera Therapeutics in a report on Wednesday, July 8th. Wedbush reiterated a “neutral” rating and issued a $34.00 target price on shares of Vera Therapeutics in a report on Monday, August 17th. Evercore set a $91.00 price target on shares of Vera Therapeutics in a research report on Friday, May 15th. Guggenheim upped their price objective on shares of Vera Therapeutics from $56.00 to $76.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Finally, HC Wainwright decreased their price objective on shares of Vera Therapeutics from $125.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $81.15.

Vera Therapeutics Trading Up 4.6%

The stock has a market capitalization of $2.54 billion, a PE ratio of -6.02 and a beta of 0.92. The firm has a 50-day moving average price of $36.34 and a 200-day moving average price of $37.86. The company has a current ratio of 10.92, a quick ratio of 10.92 and a debt-to-equity ratio of 0.18.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Monday, August 10th. The company reported ($1.52) EPS for the quarter, topping analysts’ consensus estimates of ($1.58) by $0.06. During the same period in the prior year, the firm earned ($1.20) EPS. As a group, equities analysts forecast that Vera Therapeutics, Inc. will post -6.43 EPS for the current fiscal year.

Insider Buying and Selling

In other Vera Therapeutics news, CEO Marshall Fordyce sold 46,250 shares of Vera Therapeutics stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total value of $1,956,375.00. Following the sale, the chief executive officer owned 151,994 shares of the company’s stock, valued at approximately $6,429,346.20. The trade was a 23.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 15.90% of the company’s stock.

Institutional Investors Weigh In On Vera Therapeutics

Several large investors have recently modified their holdings of the stock. Optimize Financial Inc increased its stake in Vera Therapeutics by 1.5% in the fourth quarter. Optimize Financial Inc now owns 17,800 shares of the company’s stock valued at $901,000 after acquiring an additional 256 shares during the last quarter. Virtus Investment Advisers LLC lifted its stake in Vera Therapeutics by 5.7% during the fourth quarter. Virtus Investment Advisers LLC now owns 5,342 shares of the company’s stock worth $271,000 after purchasing an additional 290 shares during the last quarter. Intech Investment Management LLC boosted its holdings in shares of Vera Therapeutics by 2.4% in the 4th quarter. Intech Investment Management LLC now owns 17,838 shares of the company’s stock worth $903,000 after purchasing an additional 424 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of Vera Therapeutics by 2.0% in the 2nd quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock worth $656,000 after purchasing an additional 550 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey increased its position in shares of Vera Therapeutics by 5.5% during the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 15,027 shares of the company’s stock valued at $761,000 after purchasing an additional 778 shares during the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.